Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.
糖尿病藥物中的胰高血糖素樣肽-1受體激動劑和鈉-葡萄糖共轉運蛋白2抑制劑對心臟衰竭和認知障礙的保護作用：潛在的保護效應機制。
Front Pharmacol 2024-07-01
Sodium-glucose cotransporter-2 inhibitors protect tissues <i>via</i> cellular and mitochondrial pathways: Experimental and clinical evidence.
藉由細胞和粒線體途徑，鈉葡萄糖共同轉運蛋白-2抑制劑保護組織：實驗和臨床證據。
World J Exp Med 2024-07-01
Whiteness and greenness assessments of a sensitive HPLC method with fluorimetric detection for dapagliflozin quantitation in human plasma: Application to a healthy human volunteer.
一種敏感的高效液相色譜法結合螢光檢測用於人體血漿中達帕格列酮的定量的白度和綠度評估：應用於健康人義工。
Arch Pharm (Weinheim) 2024-06-29
Chronic Kidney Disease Eligible for SGLT2 Inhibitors Through the Integration of Italian Administrative and Primary Care Data.
透過整合義大利行政和初級保健數據，慢性腎臟病適合使用SGLT2抑制劑。
G Ital Nefrol 2024-06-29
Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial.
empagliflozin對植入式心臟除顫器治療的2型糖尿病患者心室心律失常的影響：EMPA-ICD試驗。
Cardiovasc Diabetol 2024-06-29
Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
SGLT-2 抑制劑在重度心臟衰竭患者的心包脂肪組織中誘導抗炎和抗ferroptotic轉變。
Cardiovasc Diabetol 2024-06-29
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.
SGLT2 抑制劑 Dapagliflozin 增加 II 型糖尿病患者骨骼肌和腦部脂肪酸攝取：隨機雙盲安慰劑對照正子發射斷層掃描研究。
Diabetes Care 2024-06-28